Citi notes that the Trump administration announced that Eli Lilly (LLY) and Novo Nordisk (NVO) have agreed to significantly lower GLP-1 prices, stating that while the firm does think TrumpRx presents a threat to Hims & Hers’ (HIMS) compounded GLP-1 franchise, it views the pricing as “less bad than feared” as $150 per month was expected and Hims remains the cheapest option. The firm, which also expects to see additional compounded price reductions, particularly as orals come to market, has a Sell rating and $30 price target on Hims & Hers shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire
- Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism
- Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy
- Hims & Hers up 4.7% on report of drugmakers near deal for obesity drug prices
- Hims & Hers price target lowered to $59 from $66 at Seaport Research